By Fraiser Kansteiner
In the aftermath of an Alzheimer's patient's death, Biogen and industry watchers have been trying to piece together the situation and determine whether the company's recently minted Alzheimer's drug should carry any blame. The answer? Probably so, one analyst says.
read more
By Rebecca Torrence
Pharmacy and retail giant CVS Health plans to close 900 of its stores over the next three years as the company shifts its retail strategy for a new wave of digital consumers.
read more
By Angus Liu
As Biohaven’s fast-growing Nurtec ODT pressures rival migraine prevention medicines, one injectable player decided to bring the fight to the oral drug with a head-to-head clinical trial.
read more
By Conor Hale
The two-part deal includes a $180 million equity investment in the company alongside a $90 million discovery and development partnership that spans the next three years.
read more
By Kyle LaHucik
Cassava Sciences is forging ahead with a second phase 3 trial of its troubled Alzheimer's drug just three days after revealing a federal investigation into the company.
read more
By Paige Minemyer,Dave Muoio
CommonSpirit Health said it is "currently in discussions" with an unnamed third party regarding 14 hospitals and other clinics that it tried to hand off to Essentia Health earlier this year.
read more
By Angus Liu
Novartis is getting a huge influx of cash from selling its 20-year stake in Roche, triggering speculation about where the Swiss pharma will spend the money. Another large acquisition could be next, with a familiar face now reportedly on the shopping list.
read more
By Annalee Armstrong
Nonalcoholic fatty liver disease has claimed another victim, this time Bristol Myers Squibb is washing its hand of the midstage asset pegbelfermin. The New York Big Pharma has discontinued development of the therapy, formerly known as BMS-986036, after getting a peak at results from the phase 2b FALCON study.
read more
By Conor Hale
With more self-contained models potentially on their way to patients, the FDA is taking steps to remind healthcare providers of certain risks posed by leadless pacemakers, including the possibility of puncturing the heart wall during implantation.
read more
By Paige Minemyer
The Biden administration has issued an interim final rule that requires private insurers to report prescription drug costs to the federal government.
read more
By Nick Paul Taylor
Lars Fruergaard Jørgensen has landed the major takeover he has targeted since taking over as CEO of Novo Nordisk. Having missed out on Ablynx to Sanofi in 2018, Novo Nordisk has agreed to a $3.3 billion buyout of its RNAi partner Dicerna Pharmaceuticals as part of its search for new growth drivers.
read more
By Andrea Park
If approved by the FDA, the MoveAgain system will join an exclusive club—so exclusive, in fact, that only one other brain-computer interface has so far been cleared for commercialization.
read more
By Kyle LaHucik
Researchers at the University of Heidelberg treated rat models of alcohol addiction with the active ingredient in magic mushrooms, psilocybin, and found that the psychedelic restored expression of a glutamate receptor called mGluR2. That reduced cravings and improved executive functioning, they found.
read more
By Arlene Weintraub
Scientists at Children’s National Hospital identified peptides that are unique to medulloblastoma tumors and then engineered T cells so they could recognize and target those proteins. They believe the therapy could offer a personalized immuno-oncology option for children diagnosed with this common tumor type.
read more
